Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:40:58.001Z.
Calculation as of: 2026-10-06T15:40:58.001Z.
Quote observation: 2026-10-06T15:39:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d465a3cb364884174ea279f6e96e1b331d3038a7942601b23d7c9becb19c45da
PE RATIO
N/A
Market Cap
$1.13B
PE Ratio
15.22
TTM Avg
11.54
3Y Avg
13.50
5Y Avg
19.40
Market Cap
$1.10B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $1.15B | N/A | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 78.24 | 42.78 | 72.87 | 84.11 |
| Nektar Therapeutics (NKTR)vs › | $1.16B | N/A | 10.01 | 10.01 | 83.50 |
| OPKO Health, Inc. (OPK)vs › | $1.15B | N/A | 38.94 | 40.17 | 40.17 |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 15.22 | 11.54 | 13.50 | 19.40 |
| Harrow Health, Inc. (HROW)vs › | $1.14B | N/A | 47.35 | 23.64 | 23.64 |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.10B | N/A | N/A | N/A | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.22B | N/A | 92.39 | 92.39 | 92.39 |
| MannKind Corporation (MNKD)vs › | $1.22B | N/A | 65.92 | 100.90 | 100.90 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$26.04
Forward EPS (Est.)
$-3.28
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
